PL3762018T3 - Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą - Google Patents

Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą

Info

Publication number
PL3762018T3
PL3762018T3 PL19721159.2T PL19721159T PL3762018T3 PL 3762018 T3 PL3762018 T3 PL 3762018T3 PL 19721159 T PL19721159 T PL 19721159T PL 3762018 T3 PL3762018 T3 PL 3762018T3
Authority
PL
Poland
Prior art keywords
alkaline phosphatase
kidney injury
acute kidney
treating sepsis
associated acute
Prior art date
Application number
PL19721159.2T
Other languages
English (en)
Inventor
Roelof Peter Pickkers
Ravindra Lall MEHTA
Patrick Thomas Murray
Michael JOANNIDIS
Erik Jan VAN DEN BERG
Jacques Salomon Robert AREND
Original Assignee
Am-Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am-Pharma B.V. filed Critical Am-Pharma B.V.
Publication of PL3762018T3 publication Critical patent/PL3762018T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL19721159.2T 2018-03-08 2019-03-08 Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą PL3762018T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862640494P 2018-03-08 2018-03-08
PCT/NL2019/050153 WO2019172766A1 (en) 2018-03-08 2019-03-08 Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury

Publications (1)

Publication Number Publication Date
PL3762018T3 true PL3762018T3 (pl) 2024-06-17

Family

ID=66349613

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19721159.2T PL3762018T3 (pl) 2018-03-08 2019-03-08 Zrekombinowana fosfataza alkaliczna do zastosowania w leczeniu ostrego uszkodzenia nerek związanego z sepsą

Country Status (15)

Country Link
US (2) US12178857B2 (pl)
EP (2) EP4342534A3 (pl)
JP (2) JP7502994B2 (pl)
CN (1) CN112261948B (pl)
AU (1) AU2019232395B2 (pl)
CA (1) CA3093040A1 (pl)
DK (1) DK3762018T3 (pl)
ES (1) ES2978165T3 (pl)
FI (1) FI3762018T3 (pl)
IL (1) IL277088B2 (pl)
MX (1) MX2020009002A (pl)
PL (1) PL3762018T3 (pl)
PT (1) PT3762018T (pl)
RU (1) RU2020129445A (pl)
WO (1) WO2019172766A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019207600B2 (en) 2018-01-09 2025-01-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
DK3762018T3 (da) 2018-03-08 2024-05-06 Am Pharma Bv Rekombinant alkalisk phosphatase til anvendelse i behandling af sepsis-forbundet akut nyrelæsion
EP3768302B1 (en) 2018-03-20 2025-05-07 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2020227263A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
EP3975999A4 (en) 2019-06-03 2023-07-19 Theriva Biologics, Inc. ALKALINE PHOSPHATASE FORMULATIONS AND THEIR USES
NL2025730B1 (en) 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
CN121038803A (zh) * 2023-03-21 2025-11-28 安-法玛公司 用于治疗慢加急性肾损伤的碱性磷酸酶

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1952823A1 (en) * 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
DK2717906T5 (en) 2011-06-08 2017-06-19 Am-Pharma B V APPLICATION OF ALKALISK PHOSPHATASE FOR THE CONSERVATION OF Kidney Function
WO2015112017A1 (en) * 2014-01-24 2015-07-30 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
WO2015160805A1 (en) * 2014-04-15 2015-10-22 The Brigham And Women's Hospital, Inc. Circulating kim-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
DK3762018T3 (da) 2018-03-08 2024-05-06 Am Pharma Bv Rekombinant alkalisk phosphatase til anvendelse i behandling af sepsis-forbundet akut nyrelæsion

Also Published As

Publication number Publication date
NZ768111A (en) 2024-08-30
PT3762018T (pt) 2024-05-07
IL277088A (en) 2020-10-29
AU2019232395A1 (en) 2020-10-15
JP7502994B2 (ja) 2024-06-19
FI3762018T3 (fi) 2024-04-22
EP3762018B1 (en) 2024-02-14
EP4342534A2 (en) 2024-03-27
RU2020129445A (ru) 2022-04-08
JP2021515022A (ja) 2021-06-17
ES2978165T3 (es) 2024-09-06
EP3762018A1 (en) 2021-01-13
US20250222077A1 (en) 2025-07-10
US12178857B2 (en) 2024-12-31
CA3093040A1 (en) 2019-09-12
AU2019232395B2 (en) 2025-01-23
DK3762018T3 (da) 2024-05-06
CN112261948A (zh) 2021-01-22
IL277088B2 (en) 2024-04-01
CN112261948B (zh) 2024-06-25
WO2019172766A1 (en) 2019-09-12
JP2022078186A (ja) 2022-05-24
IL277088B1 (en) 2023-12-01
US20200397870A1 (en) 2020-12-24
EP4342534A3 (en) 2024-05-22
MX2020009002A (es) 2021-02-15

Similar Documents

Publication Publication Date Title
IL277088A (en) Recombinant alkaline phosphatase for use in the treatment of acute kidney injury associated with sepsis
GB2589223B (en) Component-dependent sub-block dividing
SG11202104356VA (en) Bt1718 for use in treating cancer
IL279757A (en) Probucol for the use and treatment of mitochondrial electron transport chain dysfunction
IL272596A (en) Pridopidine for use in the treatment of ALS
IL281868A (en) Asketamine for use in the treatment of clinical depression
SG11201905878QA (en) Identity document verification
SI3934637T1 (sl) (N-)acetil-L-levcin za uporabo pri zdravljenju travmatske poškodbe možganov
GB201813876D0 (en) Treatment
SMT202600134T1 (it) Lumateperone per uso nel trattamento della schizofrenia
IL274630A (en) Emulsions for the treatment of mucosal infections
GB201800546D0 (en) Treatment
PT3288588T (pt) Agentes de reticulação melhorados de fibras de colagénio para uso no tratamento da ectasia corneana
IL288900A (en) Treatment including fxr agonists
IL280368A (en) Compounds for use in the treatment of kidney disorders
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PT3406258T (pt) Medicamento para utilização no tratamento de gota
EP3291691C0 (en) USE OF NITRATE FOR THE TREATMENT OF POST-uterine dysgalactia in monogastric mammals
GB201821147D0 (en) Mirna for use in therapy
GB2577191B (en) System for use in improving cognitive function
IL285538A (en) Combined therapies for use in cancer treatment
ZA201907017B (en) Combination therapy for use in treating retroviral infection
SG11202012889QA (en) Dosing regimens for treating hypoxia-associated tissue damage
GB201804837D0 (en) Diagnostic methods in treatments in equine dieases
SG10201910408QA (en) Device for treating dysarthrosis